Merger and Acquisition Round Up - November 21 to 25, 2016

India Infoline News Service | Mumbai | November 25, 2016 15:45 IST

This week, ZEEL acquires General Entertainment TV Channels from Reliance Group Entities, Novartis acquires Selexys Pharmaceuticals. IIFL presents a weekly snapshot of all the major happenings in the Merger and Acquisition space, nationally and internationally.

Top News
 
Sun Pharma to acquire Biosintez in Russia
Sun Pharma  announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is US $ 24 million. Sun Pharma would also assume a debt of approximately US $ 36 million as part of this transaction. Read More
 
Domestic News
 
ZEEL acquires General Entertainment TV Channels from Anil Ambani led Reliance Group Entities
Board of Directors of Zee Entertainment Enterprises Limited (ZEEL) approved the acquisition of the General Entertainment Broadcasting Business Undertaking of Reliance Big Broadcasting Private Limited, Big Magic Limited & Azalia Broadcast Private Limited, all part of Anil Ambani led Reliance Group Entities through a scheme of demerger and execution of definitive agreements in relation to such proposed acquisition (the “Proposed Transaction”). Read More
 
Cipla EU divests stake in Chase Pharmaceuticals to Allergan
Cipla Limitedone of India’s leading pharmaceutical companies announced that Chase Pharmaceuticals Corporation, a Delaware based corporation (Chase) (in which Cipla Limited’s UK arm, Cipla (EU) Limited (Cipla UK) has 16.7% stake) has been acquired by a subsidiary of Allergan, plc. Read More
 
Reliance Capital acquires 5% voting rights in Azalia Media
Reliance Capital Ltd has informed BSE that the company has acquired more than 5% voting rights in Azalia Media Services Private Limited. Read More
 
International News
 
Novartis acquires Selexys Pharmaceuticals in deal worth up to $ 665 million
Novartis has acquired US based Selexys Pharmaceuticals Corp., a developer of therapeutics for blood and inflammatory disorders. The terms of the deal could amount to up to $ 665 million in upfront, acquisition and milestone payments, the company said. Read More

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.